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Abstract Many primary response genes, including cyclooxy-
genase-2 (COX-2), exhibit mRNA superinduction following 
agonist stimulation in the presence of translational blockers 
such as cycloheximide. This is widely assumed to result from 
mRNA stabilisation. However, superinduction of IL-1 ^-induced 
COX-2 mRNA levels by cycloheximide in pulmonary type II 
A549 cells occurred by increased transcription and not by mRNA 
stabilisation. Furthermore, equivalent effects were observed on 
NF-KB binding to COX-2 promoter KB sites and activation of the 
Jun N-terminal kinases (JNK), p54 and p46. These signalling 
pathways play important roles in COX-2 induction and may 
therefore account for the observed increases in COX-2 
transcription. These data are consistent with negative feed-back 
involving down-regulation of NF-KB by de novo IKB(X synthesis 
and suggest that JNK activation may also be down-regulated by 
a cycloheximide sensitive process. 
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1. Introduction 
Prostaglandins (PGs) are potent paracrine and autocrine 
lipid mediators that are implicated in many pathophysiolog-
ical processes, including inflammation. PGs are produced by 
many cell types, including inflammatory cells and both endo-
thelial and epithelial cells [1]. The first dedicated step in PG 
synthesis is conversion of arachidonic acid, released from 
membrane phospholipids by phospholipase enzymes, to 
PGH2 by the two cyclooxygenase (COX) enzymes [1]. COX-
1 is a constitutively expressed housekeeping gene, whilst 
COX-2 is required for mitogen-dependent PG synthesis and 
generally shows a low basal expression that is rapidly induced 
by pro-inflammatory stimuli [1-3]. COX is the main target for 
non-steroidal anti-inflammatory drugs (NSAIDs) [1], whose 
anti-inflammatory benefits derive from COX-2 inhibition, 
whilst many of the undesirable side effects are due to COX-
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1 inhibition [1]. Use of isoform-specific inhibitors confirms 
this and highlights the importance of COX-2 in inflammation 
[4,5]. 
Primary response genes, which include growth factors, cy-
tokines and transcription factors, are genes whose mRNA 
induction is refractory to translational blockade [6]. Further-
more, many of these mRNAs are actually induced by trans-
lational blockers such as cycloheximide and exhibit mRNA 
superinduction by agonist in the presence of a translational 
inhibitor. These genes are often associated with rapid mRNA 
turnover and many contain multiple AU-rich elements [7], 
which are thought to confer instability, in their 3' untrans-
lated regions (3'-UTR) [8]. Consequently, superinduction is 
commonly attributed to decreased mRNA turnover. However, 
increased nuclear signalling may also explain this effect [9]. 
COX-2 was cloned as a superinducible gene and in common 
with human bronchial epithelial cells, pulmonary type II A549 
cells show increased PGE2 release via transcriptional induc-
tion of COX-2 in response to pro-inflammatory cytokines [10-
13]. We have examined COX-2 superinduction in these cells 
and show that increased nuclear signalling via the JNK and 
N F - K B pathways may play an important role. 
2. Materials and methods 
2.1. Cell culture 
A549 cells were grown to confluency as described [12]. Cells were 
incubated over-night in serum-free media before changing to fresh 
media containing cytokines, drugs or vehicle. IL-1|3 (2x10° U/ug) 
(Genzyme, MA, USA), cycloheximide (Sigma, Poole, UK) and actino-
mycin D (Sigma) were used at 1 ng/ml, 10 ug/ml and 10 ug/ml re-
spectively. 
2.2. RNA extraction and semi-quantitative reverse 
transcriptase-polymerase chain reaction (RT-PCR) 
RNA was extracted and reverse transcription reactions and PCR 
for COX-2 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
performed as previously described [12]. The number of amplification 
cycles used was that necessary to achieve exponential amplification 
where product formation is proportional to starting cDNA and in 
each case was determined as described [12]. Products were run on 
1.5% agarose gels and Southern hybridisation performed with cloned 
cDNA probes to confirm product identity and, as all primer pairs 
cross introns, checked against possible amplification of genomic 
DNA [12]. Further aliquots were dot-blotted, hybridised as above 
and quantified by Cerenkov counting. Linearity of the relationship 
between starting cDNA concentration and product formation using 
this methodology has previously been shown [12]. Data are expressed 
as a ratio of COX-2 to GAPDH and relative values plotted as means 
±S.E.M. 
2.3. Northern blotting and hybridisation 
RNA (10 u.g) was size fractionated by electrophoresis on 1.0% 
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agarose/formaldehyde gels in 1 X MOPS. Capillary blotting and hy-
bridisation was performed according to standard procedures [14]. Hy-
bridisation probes for COX-2 and GAPDH were as above. 
2.4. Nuclear run-on transcription assay 
Nuclei, prepared as described by Greenberg and Ziff [15], were 
resuspended at 5Xl07/100 ul in 10 mM Tris-HCl (pH 7.5), 5 mM 
MgCl2, 0.5 M Sorbitol, 2.5% Ficoll, 0.008% spermidine, 1 mM DTT, 
50% glycerol and stored at —70°C. Radiolabelled RNA from run-off 
transcription reactions using 5X 107 nuclei was extracted and hybrid-
isation carried out against 10 ug of immobilised denatured plasmid 
DNA as described by Rousell et al. [14]. Plasmids used were pGEM3z 
(Promega), cloned GAPDH cDNA [12], and 2029 bp of COX-2 
cDNA (bases 2-2030) [2] cloned into pGEM5z (Promega). Following 
hybridisation, filters were washed in: Buffer A (300 mM NaCl, 10 
mM Tris-HCl, pH 7.4, 2 mM EDTA, 0.1% SDS), room temperature, 
15 min; Buffer A, 50°C, 30 min; Buffer B (10 mM NaCl, 10 mM Tris-
HCl, pH 7.4, 2 mM EDTA, 0.4% SDS), 50°C, 30 min; Buffer A plus 
1 ug/ml RNase A and 10 U/ml RNase Tl , 37°C, 30 min; Buffer A, 30 
min, 55°C; and finally Buffer B, 30 min, 55°C before autoradiogra-
phy. 
2.5. Electrophoretic mobility shift assay (EMSA) 
Nuclear proteins (2-10 ug) were used in binding reactions as de-
scribed previously [16]. After incubation on ice for 10 min, 0.0175 
pmol of 32P kinase labelled double-stranded oligonucleotide probe 
was added. Putative N F - K B elements from the COX-2 promoter 
(sense strand) used were: KBU, 5'-GGA GAG GGG ATT CCC 
TGC GC-3', and KBd, 5'-GAG TGG GGA CTA CCC CCT CT-3'. 
Specificity was determined by the prior addition of 100-fold excess of 
unlabelled competitor oligonucleotide. Reactions were separated on 
7%> native acrylamide gels before vacuum drying and autoradiogra-
phy. 
2.6. Jun N-terminal kinase (JNK) assay 
Cells in 6 well plates were harvested in 100 ul of 1% Triton X-100, 
0.5% SDS, 0.75% deoxycholate, 10 mM Tris-Cl pH 7.4, 75 mM NaCl, 
10 mM EDTA, 0.5 mM PMSF, 2 mM Na-orthovanadate, 10 ug/ml 
leupeptin, 25 ug/ml aprotinin, 1.25 mM NaF, 1 mM Na-pyrophos-
phate. An equal volume of 100 mM Tris-HCl pH 6.8, 4% SDS, 20% 
glycerol, 0.05% bromophenol blue, 5 mM P-mercaptoethanol was 
added and the sample boiled for 5 min. JNK kinase activity was 
determined using an 'in gel' renaturation assay using GST-c-Jun (1-
135) as substrate [17]. Briefly, total protein was size fractionated on 
10%o SDS-PAGE containing 1.25 mg/ml bacterially expressed GST-c-
Jun (1-135). Gels were washed in 50 mM Tris-HCl, pH 8.0, 20% 
isopropanol for 3 X 20 min to remove SDS, before further washing 
in 50 mM Tris-HCl, pH 8.0 5 mM fjME for 3 X 20 min. Proteins are 
then denatured in 50 mM Tris-HCl pH 8.0, 6 M Guanidine HC1, 
5 mM PME. Renaturation occurs during incubation at 4°C for 18 h 
in 5 changes of 50 mM Tris-HCl pH 8.0, 5 mM 0ME, 0.04% Tween. 
Gels were then soaked in 10 mM HEPES pH 8.0, 0.1 mM EGTA, 
5 mM MgCl2, 25 uM ATP, 200 mM DTT and 12.5 uCi y^P-ATP. 
After washing in 5 changes of 5% TCA, 1% w/v sodium pyrophos-
phate for 18 h, gels were vacuum dried before autoradiography. 
2.7. Western blotting and immunodetection 
Total protein was harvested as above, fractionated by 10% SDS-
PAGE and transferred to hybond-ECL membranes (Amersham, 
Buckinghamshire, UK). Immunodetection of threonine 183/tyrosine 
185 (TPY) phosphorylated and non-phosphorylated p54 and p46 
was performed according to the manufacturer's instructions (New 
England Biolabs, Hitchin, UK). IKBOI immunodetection was per-
formed with 1 in 1000 dilutions of primary antibody (Santa Cruz, 
CA, USA) and 1 in 4000 dilutions of anti-rabbit secondary antibody 
(Dako Ltd, Bucks, UK) using the ECL protocol according to the 
manufacturers instructions (Amersham). 
3. Results and discussion 
3.1. Cycloheximide superinduces IL-l/5-induced COX-2 mRNA 
We have previously shown that the IL-ip-induced rise in 
COX-2 protein, activity and PGE2 release by A549 cells is 
prevented by either transcriptional or translational blockers 
Fig. 1. Effect of IL-ip and cycloheximide on COX-2 mRNA levels. 
Cells were not stimulated (NS) or stimulated with IL-ip either with 
or without cycloheximide (Hex) as indicated. Cells were harvested at 
2 h and RNA prepared for semi-quantitative RT-PCR. A: Autora-
diographs showing RT-PCR products for COX-2 and GAPDH after 
Southern hybridisation analysis. PCR products were dot-blotted and 
hybridised with appropriate cDNA probes to allow quantification 
by Cerenkov counting. B: Data (n = 5) were expressed as ratios of 
COX-2/GAPDH and plotted as a percentage of IL-ip stimulated. 
C: Cells were either not stimulated (o), or treated with IL-ip (•) 
or IL-ip+cycloheximide (■) and harvested for RNA at the times in-
dicated. After semi-quantitative RT-PCR, data (« = 3^t) were ex-
pressed as ratios of COX-2/GAPDH and plotted as a percentage of 
t = 0. All data are plotted as means ± S.E.M. 
[12,13]. Furthermore, IL-lp elevates COX-2 mRNA primarily 
by transcriptional activation rather than via mRNA stabilisa-
tion [13,18]. As COX-2 was isolated as a superinducible pri-
mary response gene in NIH 3T3 cells [10], we investigated this 
effect in A549 cells. Alone, IL-ip caused a 5-10-fold increase 
in steady state COX-2 mRNA levels (Fig. 1A and B). Like-
wise, cycloheximide resulted in a substantial induction of 
COX-2 mRNA, whilst together with IL-ip a 2-2.5-fold super-
induction over IL-ip treated levels was observed. This was 
most apparent at 4-8 h where the IL-ip-induced rise in 
COX-2 mRNA reached a plateau, corresponding to reduced 
transcription [13], whilst IL-ip+cycloheximide treated mRNA 
levels continued to rise (Fig. 1C). These data suggest that 
translational blockade prevents synthesis of a protein or pro-
teins, which negatively regulate COX-2 mRNA levels. 
3.2. Effect of cycloheximide on IL-1 fi-induced COX-2 
mRNA half-life 
Translational blockade is widely assumed to cause mRNA 
stabilisation and has previously been found to increase 
mRNA half-life of many genes including COX-2 in ECV304 
cells [19]. However, we have previously used actinomycin D 
half-life studies to show that COX-2 mRNA is remarkably 
stable (ti/2 » 2 h) in A549 cells and that this stability was 
only marginally increased by IL-lp treatment [18]. Conse-
quently only limited potential exists for further stabilisation 
of COX-2 mRNA. This was examined by treating cells for 2 h 
either with IL-ip alone or simultaneously with IL-ip+cyclo-
heximide. Following addition of actinomycin D, degradation 
of COX-2 mRNA was monitored by Northern analysis (Fig. 
2). For both treatments, COX-2 mRNA levels were found to 
decrease gradually for 2 h and by 6 h no further decay was 
observed. No substantial differences in the stability of COX-2 
transcripts were observed. Indeed the gradient for the IL-ip 
plus cycloheximide samples was greater than for IL-ip alone. 
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Fig. 2. Comparison of COX-2 mRNA stability from IL-lp and IL-
ip plus cycloheximide treated cells. Cells were stimulated with IL-lp 
(A, C) or IL-lp plus cycloheximide (Hex) (B, D) and after 2 h acti-
nomycin D was added (t = 0). Cells were harvested at the times indi-
cated and RNA prepared for Northern blotting. Representative 
autoradiographs for COX-2 and GAPDH after Northern hybridisa-
tion analysis are shown (A, B). After laser densitometry of autora-
diographs data, n = 5 for IL-ip (C) and « = 6 for IL-ip plus cyclo-
heximide (D), were expressed as a percentage of t = Q and means 
used for linear regression analysis. 
Thus stabilisation of COX-2 transcripts does not account for 
the superinductive effect of cycloheximide. 
3.3. Effect of cycloheximide on COX-2 transcription 
Nuclear run-off transcription assays were performed to de-
termine whether the cycloheximide-dependent increases in 
steady state COX-2 mRNA were associated with increased 
transcription. These revealed that co-treatment of IL-1J3 and 
cycloheximide produced a 50 to 100% elevation in the rate of 
COX-2 transcription over that seen with IL-ip alone (Fig. 3). 
Alone, cycloheximide produced a marked increase in tran-
scription to levels similar to IL-lp treatment alone. We there-
fore conclude from these and the half-life data that superin-
duction of COX-2 mRNA occurs primarily via increased 
transcription. 
Fig. 3. Effect of IL-ip and cycloheximide on COX-2 transcription 
rate. Cells were not stimulated (NS) or stimulated with IL-lp either 
with or without cycloheximide (Hex) as indicated. Cells were har-
vested at 2 h and nuclear extracts prepared for run-off transcription 
analysis. A: Representative autoradiographs showing hybridisation 
of labelled run-off RNA to COX-2, GAPDH and pGEM3z plas-
mids. B: Data from two such experiments are shown as means of 
the ratio COX-2/GAPDH expressed as a percentage of IL-ip stimu-
lation. 
strength between the KBU and KBd EMSA is not due to differ-
ential loading or labelling of probe, but simply reflects the 
relative affinities of these two sites for N F - K B [13]. In resting 
cells N F - K B p50/p65 heterodimers are held inactive in the 
cytoplasm by inhibitor molecules known as IKB [24]. On stim-
ulation by IL-ip or TNFoc, IKB becomes phosphorylated and 
is targeted for rapid proteolysis to release active N F - K B , 
which is then free to translocate to the nucleus and activate 
transcription (Fig. 4C). This process is regulated by a negative 
feed-back loop in which N F - K B up-regulates IKBCC transcrip-
tion and expression to limit the response and ultimately return 
active N F - K B to resting levels [24]. Translational blockade by 
cycloheximide or transcriptional arrest by actinomycin D both 
prevent resynthesis of IKBOC and therefore explains the super-
inductive effect of these inhibitors on IL-ip-induced N F - K B 
3.4. Increased nuclear signalling by cycloheximide 
Characterisation of the COX-2 5' promoter region has 
identified putative binding sites for a number of acute phase 
transcription factors including two N F - K B sites, C/EBP or 
NF-IL6 sites and a CRE [20]. In A549 cells, IL-ip rapidly 
induces N F - K B p50/p65 heterodimers, which bind the two 
COX-2 KB sites in an IL-ip-dependent manner [13,16]. In 
addition a —917/+49 COX-2 promoter construct is transacti-
vated by N F - K B overexpression suggesting involvement of 
N F - K B in the transcriptional induction of COX-2 [13]. Other 
studies have also implicated the N F - K B , NF-IL6 and the CRE 
sites in the transcriptional induction of COX-2 [8,21-23]. Un-
like classical CREs, the COX-2 CRE site behaves like an AP-1 
site in binding c-Jun and is activated by MAP kinase path-
ways leading to activation of Jun N-terminal kinases (JNKs) 
[23]. We have therefore examined the effects of cycloheximide 
on the N F - K B and JNK signalling pathways. 
The effect of cycloheximide was tested on N F - K B binding to 
the two COX-2 N F - K B sites. Both sites showed superinduc-
tion of N F - K B binding in nuclear extracts from cells treated 
with IL-lp in the presence of cycloheximide or actinomycin D 
and enhanced binding as a result of cycloheximide or actino-
mycin D alone (Fig. 4A and B). The difference in signal 
Fig. 4. Effect of IL-ip, cycloheximide and actinomycin D on N F -
KB binding by KBU and KBd. Cells were not stimulated (NS) or 
stimulated with IL-lp either with or without cycloheximide (Hex) or 
actinomycin D (Act) as indicated. Cells were harvested at 1 h for 
nuclear extracts. Autoradiographs of EMSAs, representative of three 
experiments, for KBU (A) and KBd (B) are shown. Specific com-
plexes, as determined by competition analysis, are indicated by solid 
arrows. Cells were either not stimulated (NS) or treated with IL-lp 
both with and without cycloheximide (Hex) or actinomycin D (Act) 
for the times indicated and total protein used for SDS-PAGE and 
immunoblotting for IKBOC performed (C). Blots representative of 
three such experiments are shown. 
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Fig. 5. Effect of IL-lf} and cycloheximide on JNK activation. A: 
Cells were treated with IL-l(i for the times indicated and proteins 
harvested for in gel JNK kinase assay. A representative blot of two 
such experiments is shown. B: Cells were treated as indicated and 
harvested after 1 h for total protein. After SDS-PAGE immuno-
blotting was performed for threonine/tyrosine phosphorylated JNK 
(B). The blot from (B) was stripped and reprobed for total JNK 
protein (C). (B) and (C) are representative of four such experiments. 
The positions of JNK p54 and p46 proteins are indicated. 
(Fig. 4C). The appearance (on overexposed blots), at 120 min 
post-IL-ip+cycloheximide treatment, of low levels of IKBOC 
indicates incomplete block of protein synthesis by cyclohexi-
mide and may explain the consistently greater N F - K B super-
induction produced by actinomycin D . Fur thermore, cyclo-
heximide and actinomycin D alone result in appreciable loss 
of IKBOC, accounting for the inductive effect of these com-
pounds on N F - K B . 
Similarly, I L - l p rapidly induced p54 and p46 J N K activity 
(Fig. 5A). This peaked around 30 min post-stimulation and 
had markedly declined by 1 h suggesting the presence of neg-
ative regulatory mechanisms. Qualitatively similar results were 
obtained following immunoblott ing for phospho-JNK (data 
not shown). As J N K activity correlates with p54 and p46 
phosphorylation, the effect of cycloheximide was assessed by 
Western blotting for phospho-JNK (Fig. 5B) and total J N K 
(Fig. 5C) [25]. This revealed some degree of J N K phospho-
rylation by cycloheximide treatment and a dramatic superin-
duction of IL-ip-induced J N K phosphorylation by cyclohex-
imide. Recently, a protein phosphatase, which negatively 
regulates the E R K M A P kinase pathway, has been identified 
that is Ca 2 + -dependent , requires E R K activation and de novo 
synthesis for full activity [26]. The da ta presented here suggest 
the existence of similar regulatory mechanisms for the J N K 
pathway and are consistent with down-regulation of J N K 1/2 
by the M A P kinase phosphatases, M K P 1 and M K P 2 [27]. 
In conclusion, we show induction and superinduction of 
COX-2 m R N A by cycloheximide in A549 cells. These effects 
are primarily mediated at the level of transcription and not by 
m R N A stabilisation. Furthermore, we present data showing 
that cycloheximide results in activation of two major signal-
ling pathways, both of which are known to play key roles and 
may act co-operatively in the transcriptional activation of 
COX-2. We therefore conclude that in these cells superinduc-
tion by translational blockers is the result in increased nuclear 
signalling and may occur via activation of the N F - K B and/or 
J N K pathways. 
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